NCT00472641 is a Phase 4 clinical trial of Ziprasidone/Geodon in Bipolar Disorder, sponsored by Stanford University.

Who is sponsoring NCT00472641?

NCT00472641 is sponsored by Stanford University.

What drugs are being tested in NCT00472641?

Interventions in NCT00472641: Ziprasidone/Geodon.

What condition does NCT00472641 study?

NCT00472641 studies Bipolar Disorder.

Is NCT00472641 still recruiting?

NCT00472641 is currently completed. Last updated 29 March 2017.

Are results published for NCT00472641?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-03-29 · How we verify

NCT00472641

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder

Completed Phase 4 Results posted Last updated 29 March 2017

What this trial tests

Phase 4 trial testing Ziprasidone/Geodon in Bipolar Disorder in 25 participants. Completed in 1 December 2009.

Timeline

1 January 2007

Primary endpoint
1 December 2009

1 December 2009

Quick facts

Lead sponsor	Stanford University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 January 2007
Primary completion	1 December 2009
Estimated completion	1 December 2009
Sites	1 location across United States

Drugs / interventions tested

Ziprasidone/Geodon — full drug profile →

Conditions studied

Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

Stanford University

Who can join

Adults 18 to 65, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Primary Outcome Measure Was Weight Change From Baseline to Endpoint.
Time frame: Baseline, 12 weeks
The primary outcome measure will be the change in weight from baseline to endpoint using a random regression mixed effects model.

Sponsor's own description

This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to be an effective medication for overweight or obese patients with bipolar disorder. There will be approximately 25 patients enrolled in this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for the management of obesity in people with bipolar disorder.
Tully A, Smyth S, Conway Y, Geddes J, et al · · 2020 · cited 18× · PMID 32687629 · DOI 10.1002/14651858.cd013006.pub2

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00472641 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 29 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00472641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing